Fewer new therapies expected for GI disorders by 2010

Will prescription drugs for gastrointestinal disorders go the way antihistamine medications did when the FDA approved a generic version of Claritin in 2002?

It would appear so, according to “Gastrointestinal Market Outlook to 2010,” published by Business Insights, a research and business intelligence consulting company.

Gastroesophageal reflux disease and peptic ulcer disease are among the most highly prevalent diseases, but because of patent expirations over the next five years, this market is forecast to have increasing generic competition and a low level of product introductions through 2010.

Gastrointestinal tract disorders affect millions of people of all ages in all geographic regions, but pharmaceutical research and development strategies in this area have now shifted to therapies for Crohn’s disease and agents for irritable bowel syndrome (IBS).

Leading gastrointestinal drugs in development

Source: The Gastrointestinal Market Outlook to 2010

Our most popular topics on Managedcaremag.com